Continuation, Resumption, and Withdrawal Rates of CGRP-mAb Treatment for Migraine Under Real-World Clinical Conditions in Which Patients Are Free to Choose Own Treatment
Under real-world clinical conditions in which patients were free to choose their own treatment, the continuation rate of CGRP-mAb treatment 12 months after treatment initiation was 58.8%, and more than half of patients remained on treatment after 24 months. The resumption rate was 76.8% and the withdrawal rate was 20.7%.
Authors
- Ryuta Saito (ORCID: https://orcid.org/0000-0002-2484-1360)
- Satoshi Maesawa (ORCID: https://orcid.org/0000-0001-7518-0171)
- S. Yamamoto
- Takafumi Tanei (ORCID: https://orcid.org/0000-0002-9251-4230)
- Yoshitaka Nagashima (ORCID: https://orcid.org/0000-0001-9346-1663)
- Hajime Hamasaki
- Toshihiko Wakabayashi
- Tomotaka Ishizaki (ORCID: https://orcid.org/0000-0001-5346-6451)
- Yusuke Nishimura (ORCID: https://orcid.org/0000-0001-9689-0586)
- Satoshi Yamashita
- Takahiro Suzuki
Institutions
- National Hospital Organization (JP)
- Nagoya Medical Center (JP)
- Nagoya University (JP)
Publication Details
- Journal
- Neurology International
- Published
- 2025-12-24
- DOI
- https://doi.org/10.3390/neurolint18010003
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00